Dermatology CRO Market is Anticipated to Grow US$ 11.04 Bn By 2030

According to the Vision Research Reports, the Global Dermatology CRO market size was valued at USD 6.17  billion in 2020 and is projected to reach US$ 11.04 billion by 2030, growing at a CAGR of 8.9% from 2021 to 2030.

Download Exclusive Sample of Report@

Growth Factors

 The rise in demand for topical dermatological medications, such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients, to treat acne is a major factor driving the market. Furthermore, increased awareness regarding skin diseases, high demand for speedy diagnosis, and an increase in the prevalence of skin cancer and other skin problems are all driving the industry forward.

Factors such as increased investment in R&D programs, a preference for outsourcing tasks due to time and cost constraints, and patent expiration in the dermatology industry are some of the key factors expected to drive the market over the forecast period. Contract research outsourcing collaborations provide cutting-edge services, thus pharmaceutical players and government agencies prefer to delegate projects to dermatology CROs, allowing the market to develop.

Report Coverage

Report Scope Details
Market Size USD 11.04 billion by 2030
Growth Rate CAGR of 8.9% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Type, Service
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned IQVIA; ICON Plc; Charles River Laboratory; Pharmaceutical Product Development, LLC

By Type Analysis

The clinical segment accounted the dermatology contract research organizations market in 2020 with a revenue share of over 76.0%. The expanding number of biologics, the growing need for personalized medicines and orphan drugs, and the demand for innovative technologies are all contributing to the segment growth.

phase III clinical trials are one of the most expensive stages of a clinical trial, outsourcing them to dermatology CROs helped the clinical segment to gain the largest revenue share in 2020. The preclinical segment is expected to expand at the highest CAGR of 8.5% over the forecast period

By Service Analysis

Clinical monitoring dominated for the largest revenue share of more than 21.0% in 2020 and is expected to maintain its position during the forecast period. This could be due to an increase in the number of clinical trials and the need to monitor those trials, which is driving up demand for services.

dermatology clinical research has been outsourced to CROs for a variety of reasons, including cost-effectiveness and technical knowledge. The use of smart analytics and real-time data capture technologies in the healthcare sector is expected to improve clinical monitoring data.

By Phase Analysis

the phase III segment accounted the market with a revenue share of over 51.0% as phase III clinical studies are the costliest and involve a large number of participants. With 59 novel therapeutic medicines approved by the FDA between 2015 and 2016, the median cost of a single-phase III clinical study is roughly USD 19.0 million.

Phase III also necessitates a larger number of patients and, in many cases, a longer treatment term. The phase II segment held the second-largest revenue share in 2020. This research is split into two parts. The first step involves looking at a variety of doses as well as efficacy trials, and the second half involves deciding on a dose.

By Regional Analysis

Asia Pacific accounted the market with a revenue share of over 41.0% and is expected to grow rapidly in the years to come. This is due to the high prevalence of chronic illnesses, the availability of different populations, the ease with which patients may be recruited and retained, and the implementation of laws that meet acceptance criteria.

Due to the biggest number of trials conducted and outsourced in the area, the market for dermatology CROs in North America captured a significant revenue share in 2020. The growth of this regional market has also been fueled by the increasing government support for R&D activities through grants and money to research institutes and corporations.

Key Players

  • Covance Inc.
  • Pharmaceutical Product Development, LLC (PPD)
  • Parexel International Corporation
  • Charles River Laboratories International, Inc.
  • Icon, Plc
  • Medidata Solutions, Inc.
  • Syneos Health
  • Pharmaron
  • GVK Biosciences Private Limited
  • Wuxi AppTec
  • PRA Health Sciences
  • CTI Clinical Trial & Consulting
  • Bioskin
  • Proinnovera
  • Biorasi
  • Javara
  • TFS

Market Segmentation

  • By Type
    • Drug Discovery
      • Target Validation
      • Lead Identification
      • Lead optimization
    • Preclinical
    • Clinical
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
  • By Service
    • Project Management/Clinical Supply Management
    • Data Management
    • Regulatory/Medical Affairs
    • Medical Writing
    • Clinical Monitoring
    • Quality Management/Assurance
    • Bio-statistics
    • Investigator Payments
    • Laboratory
    • Patient and Site Recruitment
    • Technology
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
      • Chile
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Iran
      • Israel

Buy this Research Report study@

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape        List of Suppliers        List of Buyers

Chapter 7.  Global Dermatology CRO Market, By Type

7.1.  Dermatology CRO Market, by Type, 2021-2030

7.1.1.    Drug Discovery        Market Revenue and Forecast (2017-2030)

7.1.2.    Preclinical        Market Revenue and Forecast (2017-2030)

7.1.3.    Clinical        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Dermatology CRO Market, By Services

8.1.  Dermatology CRO Market, by Services, 2021-2030

8.1.1.    Project Management/Clinical Supply Management        Market Revenue and Forecast (2017-2030)

8.1.2.    Data Management        Market Revenue and Forecast (2017-2030)

8.1.3.    Regulatory/Medical Affairs        Market Revenue and Forecast (2017-2030)

8.1.4.    Medical Writing        Market Revenue and Forecast (2017-2030)

8.1.5.    Clinical Monitoring        Market Revenue and Forecast (2017-2030)

8.1.6.    Quality Management/Assurance        Market Revenue and Forecast (2017-2030)

8.1.7.    Bio-statistics        Market Revenue and Forecast (2017-2030)

8.1.8.    Investigator Payments        Market Revenue and Forecast (2017-2030)

8.1.9.    Laboratory        Market Revenue and Forecast (2017-2030)

8.1.10.  Patient and Site Recruitment      Market Revenue and Forecast (2017-2030)

8.1.11.  Technology      Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Dermatology CRO Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Type (2017-2030)

9.1.2.    Market Revenue and Forecast, by Services (2017-2030)

9.1.3.    U.S.        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.1.4.    Rest of North America        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Type (2017-2030)

9.2.2.    Market Revenue and Forecast, by Services (2017-2030)

9.2.3.    UK        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.2.4.    Germany        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.2.5.    France        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.2.6.    Rest of Europe        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Type (2017-2030)

9.3.2.    Market Revenue and Forecast, by Services (2017-2030)

9.3.3.    India        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.3.4.    China        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.3.5.    Japan        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.3.6.    Rest of APAC        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Type (2017-2030)

9.4.2.    Market Revenue and Forecast, by Services (2017-2030)

9.4.3.    GCC        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.4.4.    North Africa        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.4.5.    South Africa        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.4.6.    Rest of MEA        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Type (2017-2030)

9.5.2.    Market Revenue and Forecast, by Services (2017-2030)

9.5.3.    Brazil        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

9.5.4.    Rest of LATAM        Market Revenue and Forecast, by Type (2017-2030)        Market Revenue and Forecast, by Services (2017-2030)

Chapter 10.  Company Profiles

10.1.              IQVIA HOLDINGS INC.

10.1.1.  Company Overview

10.1.2.  Type Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Covance Inc.

10.2.1.  Company Overview

10.2.2.  Type Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Pharmaceutical Product Development, LLC (PPD)

10.3.1.  Company Overview

10.3.2.  Type Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Parexel International Corporation

10.4.1.  Company Overview

10.4.2.  Type Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Charles River Laboratories International, Inc.

10.5.1.  Company Overview

10.5.2.  Type Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Icon, Plc

10.6.1.  Company Overview

10.6.2.  Type Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Medidata Solutions, Inc.

10.7.1.  Company Overview

10.7.2.  Type Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Syneos Health

10.8.1.  Company Overview

10.8.2.  Type Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Pharmaron

10.9.1.  Company Overview

10.9.2.  Type Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           GVK Biosciences Private Limited

10.10.1.               Company Overview

10.10.2.               Type Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms

Buy this Research Report study@

Contact Us:

Vision Research Reports

Call: +1 9197 992 333